NEW YORK – These days "it's almost mandatory to have a session" on immune-oncology, noted Roth Capital's Jotin Marango, kicking off the 21st annual BIO CEO & Investor meeting with a panel on reshaping the tumor microenvironment via immunotherapies. But, despite the excitement generated by what's happening in the field, there's "so much nuance and few people actually understand and appreciate it all," he added.